A case of BRAF mutation-positive recurrent ovarian high-grade serous carcinoma with remarkable response to combined dabrafenib and trametinib therapy

Comprehensive genomic profiling (CGP) testing is increasingly used to identify new treatment options for solid tumors lacking standard therapies. While dabrafenib and trametinib combination therapy has shown efficacy in BRAF mutation-positive solid tumors, reports in gynecologic cancers are limited. We report a case of a patient with BRAF mutation-positive recurrent ovarian high-grade serous carcinoma who showed a remarkable response to dabrafenib and trametinib. The patient initially received monotherapy but experienced disease progression. CGP testing revealed a BRAF mutation, leading to the initiation of combination therapy. Tumor markers significantly decreased, and the recurrent pelvic lesion shrank markedly, resulting in a complete response. The patient remains recurrence-free after 9 months of treatment. This case underscores the importance of CGP testing in identifying targeted therapies for solid tumors without standard treatment options.